File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival
  • Basic View
  • Metadata View
  • XML View
TitleFat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival
 
AuthorsMan, K2
Zhao, Y2 1
Xu, A2
Lo, CM2
Lam, KSL2
Ng, KT2
Ho, JWY2
Sun, CK2
Lee, TK2
Li, XL2
Fan, ST2
 
KeywordsAnti-steatosis
Cell survival signaling
Hepatic microcirculation
Liver transplantation
Marginal graft
 
Issue Date2006
 
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
 
CitationAmerican Journal Of Transplantation, 2006, v. 6 n. 3, p. 467-476 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1600-6143.2005.01201.x
 
AbstractOwing to the discrepancy between organ donation and the demand for liver transplantation, expanding the liver donor pool is of vital importance. However, marginal liver grafts, such as small-for-size and/or fatty grafts, were associated with primary graft nonfunction or poor function. Therefore, novel combination therapies to rescue small-for-size fatty liver grafts should be investigated. In this study, we applied a combination therapy using a fat-derived hormone adiponectin (anti-steatosis) plus immunomodulator FTY720 (anti-inflammatory) in a rat liver transplantation model using small-for-size fatty liver grafts, and investigated the underlying protective mechanism such as anti-steatosis, intra-graft energy metabolism, hepatic microcirculatory changes, cell signaling cascades for survival, apoptosis and inflammation. The current study demonstrated that even a single treatment of adiponectin or FTY720 improved the 7-day graft survival from 0% to 62.5% (p = 0.001). The combination therapy significantly increased the 7-day graft survival rate to 100% by remarkable attenuation of graft steatosis and acute phase inflammatory response, significant activation of cell survival Akt pathway and maintenance of intra-graft adenosine triphosphate metabolism and improvement of hepatic microcirculation. In conclusion, the fat-derived hormone adiponectin combined with FTY720 might be a novel combination drug therapy for prevention of small-for-size fatty liver graft injury. © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.
 
ISSN1600-6135
2013 Impact Factor: 6.190
 
DOIhttp://dx.doi.org/10.1111/j.1600-6143.2005.01201.x
 
ISI Accession Number IDWOS:000235224200005
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorMan, K
 
dc.contributor.authorZhao, Y
 
dc.contributor.authorXu, A
 
dc.contributor.authorLo, CM
 
dc.contributor.authorLam, KSL
 
dc.contributor.authorNg, KT
 
dc.contributor.authorHo, JWY
 
dc.contributor.authorSun, CK
 
dc.contributor.authorLee, TK
 
dc.contributor.authorLi, XL
 
dc.contributor.authorFan, ST
 
dc.date.accessioned2010-09-06T07:43:02Z
 
dc.date.available2010-09-06T07:43:02Z
 
dc.date.issued2006
 
dc.description.abstractOwing to the discrepancy between organ donation and the demand for liver transplantation, expanding the liver donor pool is of vital importance. However, marginal liver grafts, such as small-for-size and/or fatty grafts, were associated with primary graft nonfunction or poor function. Therefore, novel combination therapies to rescue small-for-size fatty liver grafts should be investigated. In this study, we applied a combination therapy using a fat-derived hormone adiponectin (anti-steatosis) plus immunomodulator FTY720 (anti-inflammatory) in a rat liver transplantation model using small-for-size fatty liver grafts, and investigated the underlying protective mechanism such as anti-steatosis, intra-graft energy metabolism, hepatic microcirculatory changes, cell signaling cascades for survival, apoptosis and inflammation. The current study demonstrated that even a single treatment of adiponectin or FTY720 improved the 7-day graft survival from 0% to 62.5% (p = 0.001). The combination therapy significantly increased the 7-day graft survival rate to 100% by remarkable attenuation of graft steatosis and acute phase inflammatory response, significant activation of cell survival Akt pathway and maintenance of intra-graft adenosine triphosphate metabolism and improvement of hepatic microcirculation. In conclusion, the fat-derived hormone adiponectin combined with FTY720 might be a novel combination drug therapy for prevention of small-for-size fatty liver graft injury. © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationAmerican Journal Of Transplantation, 2006, v. 6 n. 3, p. 467-476 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1600-6143.2005.01201.x
 
dc.identifier.citeulike503077
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1600-6143.2005.01201.x
 
dc.identifier.epage476
 
dc.identifier.hkuros116888
 
dc.identifier.isiWOS:000235224200005
 
dc.identifier.issn1600-6135
2013 Impact Factor: 6.190
 
dc.identifier.issue3
 
dc.identifier.openurl
 
dc.identifier.pmid16468955
 
dc.identifier.scopuseid_2-s2.0-33644885246
 
dc.identifier.spage467
 
dc.identifier.urihttp://hdl.handle.net/10722/78451
 
dc.identifier.volume6
 
dc.languageeng
 
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
 
dc.publisher.placeDenmark
 
dc.relation.ispartofAmerican Journal of Transplantation
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThe definitive version is available at www.blackwell-synergy.com
 
dc.subject.meshFatty Liver - pathology - surgery
 
dc.subject.meshGraft Rejection - blood - drug therapy - pathology
 
dc.subject.meshGraft Survival - drug effects
 
dc.subject.meshImmunosuppressive Agents - therapeutic use
 
dc.subject.meshLiver Transplantation
 
dc.subjectAnti-steatosis
 
dc.subjectCell survival signaling
 
dc.subjectHepatic microcirculation
 
dc.subjectLiver transplantation
 
dc.subjectMarginal graft
 
dc.titleFat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Man, K</contributor.author>
<contributor.author>Zhao, Y</contributor.author>
<contributor.author>Xu, A</contributor.author>
<contributor.author>Lo, CM</contributor.author>
<contributor.author>Lam, KSL</contributor.author>
<contributor.author>Ng, KT</contributor.author>
<contributor.author>Ho, JWY</contributor.author>
<contributor.author>Sun, CK</contributor.author>
<contributor.author>Lee, TK</contributor.author>
<contributor.author>Li, XL</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<date.accessioned>2010-09-06T07:43:02Z</date.accessioned>
<date.available>2010-09-06T07:43:02Z</date.available>
<date.issued>2006</date.issued>
<identifier.citation>American Journal Of Transplantation, 2006, v. 6 n. 3, p. 467-476</identifier.citation>
<identifier.issn>1600-6135</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/78451</identifier.uri>
<description.abstract>Owing to the discrepancy between organ donation and the demand for liver transplantation, expanding the liver donor pool is of vital importance. However, marginal liver grafts, such as small-for-size and/or fatty grafts, were associated with primary graft nonfunction or poor function. Therefore, novel combination therapies to rescue small-for-size fatty liver grafts should be investigated. In this study, we applied a combination therapy using a fat-derived hormone adiponectin (anti-steatosis) plus immunomodulator FTY720 (anti-inflammatory) in a rat liver transplantation model using small-for-size fatty liver grafts, and investigated the underlying protective mechanism such as anti-steatosis, intra-graft energy metabolism, hepatic microcirculatory changes, cell signaling cascades for survival, apoptosis and inflammation. The current study demonstrated that even a single treatment of adiponectin or FTY720 improved the 7-day graft survival from 0% to 62.5% (p = 0.001). The combination therapy significantly increased the 7-day graft survival rate to 100% by remarkable attenuation of graft steatosis and acute phase inflammatory response, significant activation of cell survival Akt pathway and maintenance of intra-graft adenosine triphosphate metabolism and improvement of hepatic microcirculation. In conclusion, the fat-derived hormone adiponectin combined with FTY720 might be a novel combination drug therapy for prevention of small-for-size fatty liver graft injury. &#169; 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.</description.abstract>
<language>eng</language>
<publisher>Blackwell Munksgaard. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/AJT</publisher>
<relation.ispartof>American Journal of Transplantation</relation.ispartof>
<rights>The definitive version is available at www.blackwell-synergy.com</rights>
<subject>Anti-steatosis</subject>
<subject>Cell survival signaling</subject>
<subject>Hepatic microcirculation</subject>
<subject>Liver transplantation</subject>
<subject>Marginal graft</subject>
<subject.mesh>Fatty Liver - pathology - surgery</subject.mesh>
<subject.mesh>Graft Rejection - blood - drug therapy - pathology</subject.mesh>
<subject.mesh>Graft Survival - drug effects</subject.mesh>
<subject.mesh>Immunosuppressive Agents - therapeutic use</subject.mesh>
<subject.mesh>Liver Transplantation</subject.mesh>
<title>Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1600-6135&amp;volume=6&amp;issue=3&amp;spage=467&amp;epage=476&amp;date=2006&amp;atitle=Fat-derived+hormone+adiponectin+combined+with+FTY720+significantly+improves+small-for-size+fatty+liver+graft+survival</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1111/j.1600-6143.2005.01201.x</identifier.doi>
<identifier.pmid>16468955</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33644885246</identifier.scopus>
<identifier.hkuros>116888</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33644885246&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>6</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>467</identifier.spage>
<identifier.epage>476</identifier.epage>
<identifier.isi>WOS:000235224200005</identifier.isi>
<publisher.place>Denmark</publisher.place>
<identifier.citeulike>503077</identifier.citeulike>
</item>
Author Affiliations
  1. China Medical University Shenyang
  2. The University of Hong Kong